2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)

US8383637B2 · kind B2 · utility

Assignee

• Janssen Pharmaceutica NA · BE

Inventors

• Ellen Baxter · Glenside, US
• François Paul Bischoff · Vosselaar, BE
• Robert E. Boyd · Horsham, US
• Mirielle Braeken · Vlimmeren, BE
• Steve J. Coats · Quakertown, US
• Yifang Huang · Cheltenham, US
• Alfonzo D. Jordan · North Wales, US
• Chi Luo · Lansdale, US
• Marc Mercken · Turnhout, BE
• Serge Maria Aloysius Pieters · Wichelen, BE
• Allen B. Reitz · Lansdale, US
• Charles H. Reynolds · Austin, US
• Tina Morgan Ross · Limerick, US
• Brett A. Tounge · Blue Bell, US
• Mark Schulz · Skippack, US
• Hans Louis Jos De Winter · Schilde, BE

Key dates

• Filing date: Aug 4, 2005
• Grant date: Feb 26, 2013
• Expiry date: Jul 20, 2029

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D405/06
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The present invention is directed to novel 2-amino-3,4-dihydro-quinazoline derivatives, pharmaceutical compositions containing them and their use in the treatment of Alzheimer's disease (AD) and related disorders. The compounds of the invention are inhibitors of β-secretase, also known as β-site cleaving enzyme and BACE.